In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...
Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on ...
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...
The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after ...
The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results